On December 15, 2020, the CEO of Decision Diagnostics, Inc. (“DECN”) was indicted by a federal grand jury in connection with an alleged scheme to defraud investors by making false and misleading statements about the purported development of a new
Life Sciences Securities Litigation
The Life Sciences Securities Litigation blog, published by Ropes & Gray, focuses on legal issues related to securities class actions and regulatory enforcement affecting companies in the life sciences sector, including pharmaceutical, biotechnology, and medical device firms. It covers trends in securities litigation targeting life sciences companies, False Claims Act settlements, whistleblower cases, and compliance challenges such as kickback allegations and Medicaid rebate disputes. The blog also addresses large-scale settlements involving opioid litigation and other significant regulatory developments impacting life sciences corporations. It serves as a resource for understanding litigation risks, disclosure obligations, and strategies for managing securities and regulatory exposures in the life sciences industry.
Latest from Life Sciences Securities Litigation - Page 2
Johnson & Johnson and Private Equity Firm Agree to Pay $11.5 Million for Alleged FCA Violations
By Josh Levy
os Inc. (formerly affiliated with Johnson & Johnson and later sold to The Gores Group) improperly marketed a cancer treatment for uses not approved by the FDA. More specifically, the government alleged that between 2006 and 2015, Therakos marketed and…
Second Circuit Affirms Dismissal of Action Regarding Clinical Trial Of Macular Degeneration Treatment
George Lehmann, Insured Benefit Plans, Inc. v. Ohr Pharmaceutical, Inc., 2020 WL 5988517 (2nd Cir. Oct. 9, 2020)
On October 9, 2020, the Second Circuit affirmed the dismissal of an action brought against Ohr Pharmaceutical, Inc. and certain of its…
Indivior CEO Sentenced to Prison Following Park Doctrine Plea
By Josh Levy
On October 22, 2020, the former CEO of Indivior PLC, Shaun Thaxter, was sentenced to six months of imprisonment for his conviction on one misdemeanor count of misbranding in violation of the Federal Food, Drug, and Cosmetic Act (“FDCA”).
Thaxter’s…
Merit Medical Agrees to $18 Million Settlement to Resole Kickback Allegations
By Josh Levy
On October 14, 2020, the DOJ announced that it had finalized settlement negotiations with Merit Medical over allegations that Merit provided illegal payments to physicians in order to induce those providers to use Merit products. Under the guise of an…
S.D.N.Y. Rejects Proposed Amended Complaint Alleging Manufacturer Of Liver Disease Drug Intended To Commit Fraud By Not Disclosing Serious Adverse Events
Hou Liu v. Intercept Pharmaceuticals, Inc., 2020 WL 5441345 (S.D.N.Y. Sept. 9, 2020)
On September 9, 2020, Judge Lewis A. Kaplan of the Southern District of New York denied a motion to amend judgment and a request for leave to…
Mid-Year NERA Report Shows COVID-19-Related Federal Securities Litigation Targeting Pharmaceutical Industry
A recently-published report from NERA Economic Consulting provides a mid-year look back at securities class actions and demonstrates the continued focus by the plaintiffs’ securities litigation bar on health care and life science firms, particularly those focused on the development…
S.D.N.Y. Preliminarily Approves $1.6 Million Settlement in Class Action Concerning Development of an OxyContin Alternative
Shanawaz v. Intellipharmaceutics Int’l Inc., No. 17-CV-5761 (JPO) (S.D.N.Y. July 30, 2020)
On July 30, 2020, Judge J. Paul Oetken of the Southern District of New York preliminarily approved a settlement in a putative shareholder class action concerning development of…
S.D.N.Y. Partially Dismisses Claims Against Pharmaceutical Company, But Allows Claim Regarding Misleading Statements About Upcoming NDA for Rare Tissue Disorder To Proceed
Skiadas v. Acer Therapeutics Inc., 2020 WL 3268495 (S.D.N.Y. June 16, 2020)
On June 16, 2020, Judge Gregory Woods of the Southern District of New York granted in part and denied in part a motion to dismiss an action against…
Ninth Circuit Affirms Dismissal of Action Regarding Statements Concerning Likelihood of FDA Premarket Approval of Aneurysm Sealing Device
Nguyen v. Endologix, Inc., 2020 WL 3069776 (9th Cir. June 10, 2020)
On June 10, 2020, the Ninth Circuit affirmed the dismissal of a putative securities fraud class action brought against a medical device corporation, Endologix, Inc., and certain of…